What is ICANS?

TECVAYLI (Teclistamab) Everything You Need to KnowПодробнее

Module 2: Toxicity Assessment and Management | ICANSПодробнее

Treating CRS and ICANS: current approaches and future outlooksПодробнее

CAR-T Toxicities: CRS and ICANSПодробнее

Cytokine Release Syndrome (CRS) and Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS)Подробнее

ICANS/CRS Clinical PearlПодробнее

CAR T Side Effects ICANSПодробнее

Immune effector cell associated neurotoxicity syndrome ICANSПодробнее

Immune effector cell associated neurotoxicity syndrome ICANSПодробнее

CAR T-cell toxicity: CRS, ICANS and prolonged cytopeniasПодробнее

CAR T-cell toxicity: CRS, ICANS and prolonged cytopeniasПодробнее

Strategies to minimize the occurrence of CRS and ICANS in patients treated with CAR-T therapyПодробнее

What is Cytokine Release Syndrome or CRS?Подробнее

CAR T-Cell Therapy: How Does It Work?Подробнее

What are the management strategies for CRS and ICANS in MM?Подробнее

The role of microglia in the pathophysiology of ICANS following CD19 CAR-T therapyПодробнее

Investigating the co-occurrence of CRS and ICANS after CAR-T therapy & the need for novel therapiesПодробнее

What is cytokine release syndrome? #myelomaПодробнее

Nursing perspectives: a look at ICANS in CAR-TПодробнее

Management of CRS and ICANS after CAR-T therapy for ALLПодробнее